In the Margins
French pharmaceutical company Sanofi said it will seek to replace the board of Medivation after the American drug maker’s directors rejected a $9.3 billion takeover offer. Sanofi said in April that Medivation’s directors had failed to respond to its approach. Meanwhile, Medivation’s board called the offer “inadequate,” and founder and CEO David Hung has said the French company’s move was “opportunistically timed.” Read the original story from The New York Times.
Most Read
Mutual fund boards can continue conducting business—including voting on contract approvals and renewals and other important matters—virtually through the end of 2020, according to the Securities ...
Mutual fund boards seem well on their way to mastering the art of conducting business virtually, but one area that may still be a challenge during ...
A majority of independent mutual fund directors did not see a significant increase in compensation last year, particularly if they served on one of the largest ...
The world has been turned upside down in the past two months, and it remains unclear if things will ever go back to what we considered ...